Mission Bio, Inc., a South San Francisco, Calif.-based developer of high-throughput single-cell DNA and multi-omics analysis, raised $70m in Series C financing.
The round, which brought total funding to more than $120m, was led by Novo Growth with participation from Soleus Capital and earlier investors Mayfield, Cota, and Agilent. As part of this announcement, Robert Ghenchev, Senior Partner and Head of Novo Growth, has joined Mission Bio’s board of directors.
The company intends to use the funds to scale its single-cell multi-omics technology, the Tapestri® Platform, to expand its reach in more effective clinical trials for novel cancer treatments, as well as to characterize cell and gene therapy.
Led by Charlie Silver, CEO, Mission Bio delivers targeted solutions for high-impact applications with the Tapestri Platform, a single-cell multi-omics platform, enabling genotype and phenotype from the same cell and precise detection of heterogeneity in disease progression and treatment response. Application areas include oncology blood cancers, solid tumors, and genome editing validation.
Over the past year, the company has advanced its efforts to support drug development through clinical trials and the translation of research into novel biomarkers with its install base in NCI cancer centers and key biopharma companies. The technology has been adopted by Agios, LabCorp, Onconova Therapeutics, and other companies to optimize clinical trials and improve the likelihood of success. Cancer centers, including Stanford, MD Anderson Cancer Center, the University of California at San Francisco, and Memorial Sloan Kettering Cancer Center, have leveraged the Tapestri Platform to support their work in therapeutic resistance and treatment response monitoring.
Spun out of research at the University of California, San Francisco, Mission Bio is headquartered in South San Francisco, California.